Tamoxifen reduces fat mass by boosting reactive oxygen species

Area of Science:

• Metabolic research
• Obesity studies
• Animal modeling

Background:

• Obesity is a growing pandemic, necessitating robust animal models to study metabolic disorders.
• Tamoxifen (Tam) is a common inducer for Cre-lox systems in animal models, controlling gene expression.
• Concerns exist regarding Tamoxifen's intrinsic effects on adiposity, potentially confounding research.

Purpose of the Study:

• To investigate whether Tamoxifen itself influences adiposity and affects studies on target genes in adipose tissue.
• To elucidate the mechanisms behind Tamoxifen's potential impact on fat mass.

Main Methods:

• Administration of Tamoxifen to Cre-absent mice (f-FoxO1 and df-Irs).
• Assessment of changes in body weight and fat mass.
• Analysis of reactive oxygen species (ROS) production, apoptosis, and autophagy.
• Evaluation of adipogenic regulator peroxisome proliferator-activated receptor gamma (PPARγ) expression and adipocyte differentiation.

Main Results:

• Tamoxifen induced a significant ~30% reduction in fat mass without altering body weight.
• Tamoxifen promoted ROS production, apoptosis, and autophagy, leading to PPARγ downregulation and adipocyte dedifferentiation.
• ROS normalization attenuated Tamoxifen-induced apoptosis, autophagy, and adipocyte dedifferentiation.
• These effects, including ROS production and fat mass reduction, persisted for 4-5 weeks.

Conclusions:

• Tamoxifen administration can independently reduce fat mass in mice, primarily through ROS-mediated mechanisms.
• The findings highlight the necessity of a recovery period after Tamoxifen treatment to avoid confounding results in gene function studies.
• Researchers using Tamoxifen in animal models should consider its direct effects on adiposity and implement appropriate control strategies.